The Paroxysmal Nocturnal Hemoglobinuria treatment market is experiencing significant expansion, driven by increasing disease awareness, rising preval ...

The Oligonucleotides for CNS Summit returns for its 5 th year to address key challenges in durability, scalability, potency ...

The SPDR S&P Biotech ETF (XBI) made its debut on 01/31/2006, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market. The ETF industry has ...

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

Detailed price information for United Therapeutic (UTHR-Q) from The Globe and Mail including charting and trades.

J.P. Morgan analyst Jessica Fye maintained a Buy rating on Insmed today and set a price target of $111.00. The company’s shares closed yesterday at $96.95. Take advantage of TipRanks Premium at 50% ...

As the U.S. stock market experiences mixed movements with major indexes reaching record highs amidst inflation data and earnings reports, the tech sector stands out with notable rallies spurred by ...

As the United States market navigates a complex landscape marked by trade policy uncertainties and fluctuating economic indicators, major indices like the Dow Jones Industrial Average and S&P 500 ...

The increasing incidence of genetic and rare diseases is a major factor driving revenue growth in the Antisense ...

To help solve this problem, scientists are working on a new medicine called zilebesiran—and it could be a game-changer. This ...